MARIA TERESA
BERNAL DEL CASTILLO
PROFESORA TITULAR DE UNIVERSIDAD
Hospital Universitario Reina Sofia
Córdoba, España
Publicacións en colaboración con investigadores/as de Hospital Universitario Reina Sofia (38)
2026
-
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group
Bone Marrow Transplantation
-
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories
Leukemia Research, Vol. 160
-
Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study
Journal of Clinical Oncology
2025
-
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX
Cancer, Vol. 131, Núm. 1
-
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience
Transplantation and Cellular Therapy, Vol. 31, Núm. 5, pp. 299.e1-299.e14
-
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study
Cancers, Vol. 17, Núm. 5
-
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study
Cancers, Vol. 17, Núm. 17
-
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry
Leukemia, Vol. 39, Núm. 11, pp. 2686-2696
-
Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry
Haematologica
2024
-
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer, Vol. 130, Núm. 20, pp. 3436-3451
-
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670
-
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Haematologica, Vol. 109, Núm. 1, pp. 115-128
-
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study
Leukemia, Vol. 38, Núm. 10, pp. 2259-2265
-
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
Haematologica
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice
Leukemia and Lymphoma, Vol. 64, Núm. 3, pp. 679-690
-
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
HemaSphere
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice
Journal of Personalized Medicine, Vol. 13, Núm. 12